An Investigation of CYP2D6 Genotype and Response to Metoprolol CR/XL During Dose Titration in Patients With Heart Failure
Autor: | R. A. De Boer, Finn Waagstein, Jonathan Batty, Hazel L. White, John Kjekshus, John Wikstrand, Åke Hjalmarson, P. van der Harst, Alistair S. Hall, D. J. Van Veldhuisen, Anthony J. Balmforth |
---|---|
Přispěvatelé: | Cardiovascular Centre (CVC) |
Jazyk: | angličtina |
Rok vydání: | 2014 |
Předmět: |
Male
medicine.medical_specialty CYP2D6 CLINICAL-OUTCOMES PHARMACOKINETICS Genotype Adrenergic beta-Antagonists Diastole Blood Pressure Pharmacology METABOLISM OXIDATION Gastroenterology Pharmacokinetics Double-Blind Method RANDOMIZED INTERVENTION TRIAL Heart Rate Risk Factors Internal medicine CYTOCHROME-P450 2D6 medicine Humans Pharmacology (medical) Metoprolol Aged Heart Failure Dose-Response Relationship Drug business.industry BETA-BLOCKERS Hemodynamics ANKYLOSING-SPONDYLITIS Stereoisomerism DNA Middle Aged medicine.disease Treatment Outcome Cytochrome P-450 CYP2D6 Heart failure Pharmacodynamics Chronic Disease Female ADVERSE EVENTS business Pharmacogenetics medicine.drug TASK-FORCE |
Zdroj: | Clinical Pharmacology & Therapeutics, 95(3), 321-330. Nature Publishing Group |
ISSN: | 0009-9236 |
DOI: | 10.1038/clpt.2013.193 |
Popis: | To explore the pharmacogenetic effects of the cytochrome P450 (CYP) 2D6 genotype in patients with systolic heart failure treated using controlled/extended-release (CR/XL) metoprolol, this study assessed the CYP2D6 locus for the nonfunctional * 4 allele (1846G> A; rs3892097) in the Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF; n = 605). Participants were characterized as extensive, intermediate, or poor metabolizers (EMs, IMs, or PMs, respectively), based on the presence of the CYP2D6* 4 allele (EM: * 1* 1, 60.4%; IM: * 1* 4, 35.8%; and PM: * 4* 4, 3.8%). Plasma metoprolol concentrations were 2.1-/4.6-fold greater in the IM/PM groups as compared with the EM group (P |
Databáze: | OpenAIRE |
Externí odkaz: |